Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

A subset of patients treated with delgocitinib cream 20 mg/g for moderate to severe chronic eczema achieved a “super-response,” by week 16, according to a presenter at the American Academy of ...

If you’re a frequent camper or want a reliable source of power in case of blackouts or other emergencies, your best bet is to invest in a power station. This gadget can be used to power appliances, or ...

Manufacturers in the off-highway industry are facing challenges as the industry moves toward electrification, but this can be ...

BMS is setting a list price of $410,300 for Breyanzi ... and FL. For MZL, the PI3K-delta and casein kinase CK1-epsilon inhibitor can be used in patients who have previously been treated with ...

Spring is here, bringing longer days, fresh blooms, and the perfect time to uplift your mood and enhance your well-being. To celebrate, Rare Cannabinoid Company is offering a BOGO 50% off deal on its ...

Story March 18 - TC BioPharm: The Scottish biotech developing allogeneic gamma-delta T cell therapies is ... Separately, BMS also disclosed 57 job cuts at its site in Redwood City, California ...

BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy in triple negative breast cancer patients. It is expanding its existing collaboration with ...

The World Happiness Summit® (WOHASU®) returns to Miami after two years in Europe, bringing together thought leaders, researchers, change-makers, and business pioneers to explore the science of ...